Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis.
作者信息
Tefferi Ayalew, Lasho Terra L, Hanson Curtis A, Ketterling Rhett P, Gangat Naseema, Pardanani Animesh
机构信息
Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Division of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA.
出版信息
Br J Haematol. 2018 Nov;183(4):678-681. doi: 10.1111/bjh.15010. Epub 2017 Nov 23.
PMID:29171022
Abstract
摘要
Zotero 插件